<DOC>
	<DOCNO>NCT00961844</DOCNO>
	<brief_summary>In trial investigator want combine chemotherapy immunotherapy give patient Temozolomide , vaccination . The investigator also include hTERT survivin mRNA vaccine . Finally , investigator want introduce ex vivo T cell expansion lymphodepletion patient show immune response .</brief_summary>
	<brief_title>Trial Vaccine Therapy With Dendritic Cells Patients With Metastatic Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Histologically verify malignant melanoma measurable ( accord RECIST ) , unresectable metastasis ( Stage III Stage IV M1ac define criterion AJCC Cancer Staging Manual , 6 th . Edition 2002 ) . Patients melanoma unknown primary site eligible . Preferably accessible tumor tissue enough volume quality vaccine production ( extraction tumor mRNA ) Must least 18 year age Must ambulatory ECOG performance status 0 1 Life expectancy ≥ 6 month Negative MRI brain Must lab value follow : ANC ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hb ≥ 9 g/dL ( ≥ 5.6 mmol/L ) Creatinine ≤ 140 μmol/L ( 1.6 mg/dL ) ; borderline , creatinine clearance ≥ 40 mL/min Bilirubin &lt; 20 % upper limit normal ASAT ALAT ≤ 2.5 upper limit normal Albumin ≥ 2.5 g/L If patient female , must practice adequate contraception study treatment Signed informed consent expect cooperation patient treatment follow must obtain document accord ICH/GCP , national/local regulation The patient suffers ocular mucous membrane melanoma History prior malignancy melanoma , except curatively treat basal cell squamous cell carcinoma skin cervix cancer stage 1B effectively treat malignancy remission 5 year highly likely cure . Active systemic infection require intravenous antibiotic , coagulation disorder major medical illness cardiovascular , respiratory immune system . PI shall make final determination regard appropriateness enrollment Autoimmune disease currently treat systemic steroid Version . 3 , 18 June 2009 Page 17 50 Adverse reaction vaccine anaphylaxis serious reaction History immunodeficiency autoimmune disease rheumatoid arthritis , systemic lupus erythematosus , scleroderma , polymyositisdermatomyositis , juvenile onset insulin dependent diabetes , vasculitic syndrome Positive HIV , Hepatitis B C Syphilis ( treponema pallidum ) Pregnancy lactation If patient receive prior anticancer treatment , include radiotherapy , chemotherapy immunotherapy and/or immunomodulating agent , must stop least 4 week first study treatment administration . Chemotherapy , glucocorticosteroids potentially immunesuppressive therapy administer within 4 week prior vaccination No treatment dacarbazine temozolomide time prior study entry Any reason , opinion investigator , patient participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>